ERBB2 and cardiomyopathy: Taken together, these results suggest overtreatment of HR-positive, HER2-negative disease in BRCA1 and 2 PV carriers, which may expose patients unnecessarily to toxicities including neuropathy (platinums), cardiomyopathy, and secondary hematologic malignancies (anthracyclines).